论文部分内容阅读
本院自1991年起应用基因工程重组的干扰素α2b(IntronA,美国先灵葆雅公司制品)联合长程猪苓多糖长程强力宁作为慢性乙肝的抗病毒治疗,取得较满意的近期疗效,现报道如下。 1 材料与方法 1.1 病例选择 13例患者系1991～1993年本院住院患者,其中男12例,女1例。平均年龄31.2岁(16～53岁)。临床诊断慢性乙肝11例(临床归类慢活肝7例,慢迁肝4例),乙肝病毒携带者2例。诊断采用1990年
Our hospital since 1991, the use of genetically engineered recombinant interferon α2b (IntronA, the United States Schering-Plow Company products) long-term Polygonatum long-acting strong Ning as chronic hepatitis B antiviral therapy, obtained more satisfactory recent efficacy, are reported below. 1 Materials and Methods 1.1 Case Selection 13 patients were hospitalized in our hospital from 1991 to 1993, including 12 males and 1 female. The average age of 31.2 years old (16 to 53 years old). Clinical diagnosis of chronic hepatitis B in 11 cases (clinical classification of slow-living liver in 7 cases, slow-moving liver in 4 cases), hepatitis B virus carriers in 2 cases. Diagnosis used in 1990